Assessment of Safety and Efficacy of Varying Durations of Dual Antiplatelet Therapy with Aspirin and Ticagrelor Following Successful Percutaneous Coronary Intervention in Diabetic Patients with Acute Coronary Syndrome - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessment of Safety and Efficacy of Varying Durations of Dual Antiplatelet Therapy with Aspirin and Ticagrelor Following Successful Percutaneous Coronary Intervention in Diabetic Patients with Acute Coronary Syndrome

  • By

  • Nour Eldeen Mahmoud Shabaan Ibrahim

  • Mohamed Tarek Mounir Zaki

  • Khaled Ahmed Fouad Abdel Magid

  • Khaled Ahmed Fouad

  • Mina Magued Abdalla Iskandar

  • March 27, 2026

Share

  • 1

    Diabetic patients have a 2–3 times higher cardiovascular risk, making effective management of acute coronary syndrome crucial.

  • 2

    The study evaluated the impact of transitioning from dual antiplatelet therapy to ticagrelor monotherapy after 3 months on major adverse cardiovascular events.

  • 3

    400 diabetic patients with acute coronary syndrome were randomized into two groups: one receiving ticagrelor monotherapy and the other continuing dual therapy.

  • 4

    Primary outcomes included major adverse cardiovascular events, while secondary outcomes focused on bleeding events classified by BARC criteria.

  • 5

    The study adhered to CONSORT guidelines and aimed to balance the benefits of antiplatelet therapy against the risks of bleeding.

Original Source(s)

Assessment of Safety and Efficacy of Varying Durations of Dual Antiplatelet Therapy with Aspirin and Ticagrelor Following Successful Percutaneous Coronary Intervention in Diabetic Patients with Acute Coronary Syndrome

  • by Nour Eldeen Mahmoud Shabaan Ibrahim, Mohamed Tarek Mounir Zaki, Khaled Ahmed Fouad Abdel Magid, Khaled Ahmed Fouad, Mina Magued Abdalla Iskandar

  • March 27, 2026

Related Content

Pre–existing Comorbidities as Potential Risk Modifiers for New-Onset Myocarditis and Pericarditis following mRNA COVID-19 Vaccination in Males Aged 18–30 in the United States: A Disproportionality Analysis using VAERS Spontaneous Reporting Data

HHS Proposes Mandatory GRAS Notices

Manufacturers would be required to notify the FDA of GRAS determinations under a proposed rule, while HHS and USDA also submitted the first proposed federal definition of ultra-processed foods for final review.

FDA Approves New Iohexol Vials

The approval includes additional 300 mg iodine/mL and 350 mg iodine/mL vial presentations.